Here is the number nobody puts in the ads: in the STEP 1 trial extension, people who quit semaglutide regained about two-thirds of their lost weight within one year. Stopping GLP-1 weight regain is not a willpower failure — it is the documented, expected biology of a drug that quiets appetite only while it is in your body. This guide walks through the regain data for semaglutide and tirzepatide, tapering versus quitting cold, and the specific habits that separate people who keep the weight off from people who watch it return.
Stopping GLP-1 Weight Regain: What the Data Shows
The starting point is the STEP 1 trial, published in the New England Journal of Medicine. Adults taking 2.4 mg weekly semaglutide lost an average of 14.9% of body weight over 68 weeks, versus 2.4% on placebo. Then the trial did something unusually honest: an extension study followed participants for a full year after both the drug and the lifestyle support stopped.
The extension results, published in Diabetes, Obesity and Metabolism, are the clearest picture we have of what stopping actually costs. Participants regained 11.6 percentage points of lost weight between week 68 and week 120. Trial completers had lost roughly 17% on average, so they ended the year a net 5.6% below their starting weight — meaning about two-thirds of the loss came back within 12 months.
The scale was not the only thing that reverted. Improvements in blood pressure, blood sugar, and other cardiometabolic markers drifted back toward baseline for most measures by week 120. People whose blood sugar had normalized during treatment moved back toward prediabetic ranges after stopping.
Tirzepatide tells the same story. In the SURMOUNT-4 trial, published in JAMA, everyone took tirzepatide for 36 weeks and lost an average of 20.9%. Then half were switched to placebo without knowing it.
| Study | What happened | Result |
|---|---|---|
| STEP 1 (NEJM) | Semaglutide 2.4 mg for 68 weeks | −14.9% average weight loss |
| STEP 1 extension | Drug and support stopped for 1 year | Regained 11.6 points; net −5.6% |
| SURMOUNT-4 (JAMA) | Switched to placebo at week 36 | Regained 14.0% by week 88; net −9.9% |
| SURMOUNT-4 (JAMA) | Continued tirzepatide to week 88 | Lost 5.5% more; net −25.3% |
One SURMOUNT-4 number deserves bold type: at week 88, 89.5% of people who stayed on tirzepatide had kept at least 80% of their weight loss. Among those switched to placebo, only 16.6% had.
Why the Weight Comes Back
Per the Cleveland Clinic, GLP-1 drugs copy a gut hormone that slows stomach emptying and signals fullness to your brain. Those signals exist only while the drug is circulating. The medication never retrained your appetite — it replaced it.
Per the Wegovy prescribing information, semaglutide’s elimination half-life is about one week. That means drug levels fall steadily for roughly 4 to 5 weeks after your last injection, and hunger typically climbs back as levels drop. Many people feel the shift within the first few weeks: portions grow, snacking returns, and the food noise that went quiet gets loud again.
The NIDDK frames obesity as a chronic condition, and that framing explains the data. These medications manage weight the way blood pressure pills manage blood pressure — while you take them. Stopping is not failure, but it does mean the biological pressure to regain returns at full strength.
Tapering vs. Stopping Cold Turkey
There is no FDA-approved taper schedule for semaglutide or tirzepatide. The Wegovy label spells out how to climb from 0.25 mg to 2.4 mg over about 16 weeks, but it contains no plan for coming down. GLP-1s also do not cause a classic withdrawal syndrome — quitting abruptly is not dangerous the way stopping some medications is. The cost of a hard stop is speed: appetite returns in weeks, all at once.
That is why many clinicians walk patients down the same dose ladder in reverse, holding each step about 4 weeks. The honest caveat: no large trial has proven that tapering prevents regain. What a taper buys you is time — months of gradually rising appetite to practice maintenance habits against, instead of a cliff.
| Step | Weekly semaglutide dose | Typical hold |
|---|---|---|
| Starting point | 2.4 mg (maintenance) | — |
| Step down 1 | 1.7 mg | ~4 weeks |
| Step down 2 | 1 mg | ~4 weeks |
| Step down 3 | 0.5 mg | ~4 weeks |
| Step down 4 | 0.25 mg, then stop | ~4 weeks |
This table simply mirrors the FDA escalation ladder in reverse — it is an illustration, not a prescription. Your clinician may move faster, slower, or skip steps based on your history.
The Taper-Off Guarantee: A Market Example
The telehealth industry has noticed that regain fear sells. In September 2024, Noom announced a Taper-Off Guarantee tied to its 12-month compounded GLP-1 program: per Noom, if you complete the 12-month protocol with its taper and regain the weight within 18 months, the company provides a year of free Noom or substantial medication discounts. That is a refund-style marketing promise, not clinical evidence that its taper works — and it requires finishing the full 12-month program to qualify. Read the terms before you count on it.
What Actually Helps You Keep Weight Off
Per the NIDDK, weight-loss medications work best combined with changes to eating and activity. After you stop, those changes are the entire strategy. The maintenance playbook is boring, cheap, and specific.
Stopping GLP-1 Weight Regain Checklist
- Strength training 2–3 days per week. Some of the weight lost on these drugs is lean muscle, and muscle is what keeps your resting calorie burn up. Rebuilding it is the closest thing to metabolic insurance you can buy for free.
- Protein at every meal. Protein is the most filling macronutrient. With the drug gone, food choices have to generate the fullness the medication used to provide.
- Weekly weigh-ins with an action number. Pick a threshold — say, 5 pounds above your stopping weight — that automatically triggers food logging again and a call to your clinician. Reversing 5 pounds is a project; reversing 25 is a crisis.
- Keep the follow-up appointments. The STEP 1 extension removed both drug and support at once. Do not copy that design. A clinician who sees your trend early has options you do not.
- Protect sleep. Short sleep reliably pushes appetite up — the last thing you need while fullness signals are fading.
One important distinction before you blame regain: if the scale stalled while you are still taking the medication, that is a different problem with different fixes, and our GLP-1 plateau guide walks through them.
The Lower-Dose Middle Ground
Stopping is not all-or-nothing. Some patients and clinicians step down to the lowest dose that holds weight steady instead of quitting entirely, and telehealth companies now sell low-dose maintenance tiers — Noom’s microdose plan, for example, starts at $79 for the first month, then $179–$199/month per its July 2026 pricing pages. Our microdosing GLP-1 guide explains the science, which is thinner than the marketing, and our comparison of GLP-1 microdosing programs shows who sells what and at what price.
Two honest caveats belong here. Low-dose maintenance is not an FDA-labeled use — the approved maintenance dose of Wegovy is 2.4 mg weekly. And most microdose programs use compounded semaglutide, which is not FDA-approved; the FDA has warned about dosing errors and adverse events with compounded GLP-1 drugs. If you go this route, go in with clear eyes.
Weight Regain Timeline After Stopping a GLP-1
Putting the biology and the trial data together, here is the shape of the first year after your last dose.
| Time after last dose | What the data and biology suggest |
|---|---|
| Weeks 1–5 | Drug levels fall steadily; semaglutide’s ~1-week half-life means it fades, not vanishes |
| Weeks 2–8 | Hunger and portion sizes creep up for many people as fullness signals weaken |
| Months 3–6 | Regain is well underway in the trial curves; blood pressure and blood sugar begin drifting back |
| Month 12 | STEP 1 extension average: about two-thirds of lost weight regained; most cardiometabolic gains reverted |
Remember that these are averages with a wide spread — the extension reported a standard deviation of 7.7 points around that 11.6-point regain. Some people regained nearly everything; others kept most of the loss. Which side you land on is partly biology and partly whether the checklist above is running before week 2, not after month 6.
Should You Stop at All?
Semaglutide and tirzepatide are FDA-approved for chronic weight management — long-term use is the design, not the exception. Still, real life intervenes. People stop over cost, side effects, supply problems, or pregnancy: per the Wegovy prescribing information, the drug should be stopped at least 2 months before a planned pregnancy.
If cost is the driver, run the numbers before quitting outright. Cash-pay telehealth prices sit far below the $1,300+/month retail brand price, with compounded programs starting around $99/month — our comparison of the best weight loss injections lists prices verified in July 2026. And factor in the restart tax: going back on later usually means re-titrating from 0.25 mg, so months off is never a free pause. Whatever you decide, decide it with your prescriber and a written maintenance plan — the data is brutally clear about what happens with neither.